AstraZeneca (AZN) stock
AZN · AstraZeneca PLC · NYSE
- Market cap
- $270.48B
- Shares out
- 1.55B
- Open
- $176.22
- Prev close
- $175.36
- VWAP
- $175.98
Today $174.07 - $177.41
What is the latest news on AZN stock?
AZN fell 0.54% to $174.42 on Nov 20, 2026. No AZN story in the last two days; the most recent is below.
Based on CLARITY-Gastric01 Phase III trial results which showed Sone-Ve reduced the risk of death by 42% in this settingConsistent Sone-Ve efficacy data across CLDN18.2 expression levels (>25%) supports potential use in up to 60% of patients in this settingAstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity.The Food and Drug Administratio
All AZN newsWhen does AstraZeneca report earnings?
The latest AstraZeneca earnings release came out on Oct 30, 2026: AstraZeneca results: 9M and Q3 2026. Before that, AstraZeneca reported on Jul 27, 2026 and Apr 29, 2026. On that schedule the next report would come around late January 2027.
AZN earnings historyAre insiders buying or selling AZN?
Insiders are buying. In the last 90 days 1 insider bought $3K of AZN in trades reported on Form 4. The latest: Mani Sharma bought $3K, reported on Sep 11, 2026.
AZN insider tradesFinancial highlights
Full financials- Revenue, FY2025
- $58.74B
- Revenue growth
- +8.6%
- Net income, FY2025
- $10.22B
- Net margin
- 17.4%
- Free cash flow, FY2025
- $11.77B
- Cash
- $5.71B
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
Latest news
25 items- PRSonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancersBased on CLARITY-Gastric01 Phase III trial results which showed Sone-Ve reduced the risk of death by 42% in this settingConsistent Sone-Ve efficacy data across CLDN18.2 expression levels (>25%) supports potential use in up to 60% of patients in this settingAstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity.The Food and Drug Administratio
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRPerioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancerBased on VOLGA Phase III trial data which showed a 49% reduction in risk of recurrence and a 42% reduction in risk of death, with a manageable safety profile Approval reinforces potential of IMFINZI as an immunotherapy backbone across muscle-invasive and non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. T
- FDAFDA Approval for KLYGEFA issued to ALEXION PHARMSubmission status for ALEXION PHARM's drug KLYGEFA (ORIG-1) with active ingredient GEFURULIMAB has changed to 'Approval' on 11/13/2026. Application Category: BLA, Application Number: 761488, Application Classification:
- PRAstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the USUS ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $20 million to date AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative. The initiative supports programs that prioritize the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. Through the 6th annual Community Solutions Challenge (CSC), ACT on Health Equity supports nonprofit programs focused on advancing health equity across healthcare access, education, climate & nature, and nutrition & food security.
- INSIDEROfficer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)4 - ASTRAZENECA PLC (0000901832) (Issuer)
- PRGabelli Releases Agenda for 8th Annual Healthcare SymposiumPALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the Paley Center for Media in New York. The symposium will bring together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals. This symposium features three panel discussions with senior leaders from across the healthcare industry, including providers, biopharmaceutical companies, distributors, payers, and healthcare technology companies. Discussions will cover the pace of oncol
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PREnhertu® Wins 2026 International Prix Galien Award for Best Biotechnology ProductSecond Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024 Enhertu® (trastuzumab deruxtecan) has been awarded the 2026 International Prix Galien Award for Best Biotechnology Product, a recognition awarded every two years by The Galien Foundation. This is the second award granted to Enhertu, following receipt of the Prix Galien USA Award for Best Biotechnology Product in 2024. The Prix Galien is among the global health innovation industry’s most renowned honors, recognizing outstanding biomedical and medical technology product achievements that improve the human condition, and is considered the industry’s equivalent of t
- PRAstraZeneca results: 9M and Q3 2026Continued strong commercial performance and 12 positive Phase III programme readouts in the year to date AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7
- PR2027 Could Finally Be the Year Cancer Is on the Ropes!DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay attention. Artificial intelligence is helping scientists investigate treatments and connect medical knowledge. Clinical trials are showing survival gains in difficult cancers. Laboratory researchers are exploring ways to make cancer cells manufacture toxic compounds inside themselves and to guide malignant cells toward a more normal state. These advances are at different stages of development. Together, they illustrate the expanding range of approaches researchers are bringin
- PRAstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker TestingCampaign encourages people to take a "time out" to learn more about cancer biomarker testing, which can guide more personalized cancer treatment decisions AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing if they or a loved one is diagnosed with cancer, helping make biomarker testing a standard part of the cancer care conversation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028294394/en/AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Test
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PREnhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerApproval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically
- PRBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity. The investments raise a larger question: could managing obesity generate trillions of dollars in drug sales over the next two decades? Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030, with oral medicines accounting for 40% of the market. If annual sales reached that level and remained unchanged from 2030 through 2049, cumulative reven
- PRGabelli To Host 8th Annual Healthcare SymposiumPALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York. The symposium brings together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals. This year’s program will cover the pace of oncology innovation, drug access in the specialty and GLP-1 era, and the role of artificial intelligence in care delivery. For additional information and to register, please visit our website. Space is limited, so please register as soon as possible
- PRSonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this setting Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal a
- PRTAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOTAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing TAGRISSO as backbone therapy across EGFRm lung cancer Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with
- PRIMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trialNovel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial Results reinforce IMFINZI as the backbone immunotherapy across stages of small cell lung cancer Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung
- PRPerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerMore than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically meaningful survival benefit and manageable safety profile Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus stand
Hiring
Nov 22, 2026AstraZeneca PLC lists 859 open roles on its careers site as of Nov 22, 2026.
- Open roles
- 859
Counted daily from AstraZeneca PLC's careers site.
AZN rankings
- Other37(49%)
- SEC Filings32(42%)
- Insider3(4%)
- Analyst2(3%)
- Offering1(1%)
- Earnings1(1%)
Our reporting on AZN
AstraZeneca PLC (AZN) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 25 wire items for AZN, including 15 press releases and news items, 8 SEC filings and 1 earnings update. The most recent was published Nov 19, 2026.
AZN FAQ
12 questionsWhat does AstraZeneca PLC do?
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir...What is AZN revenue?
AstraZeneca PLC (AZN) reported $58.74B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 8.6% from the year before.Is AZN profitable?
Yes. AstraZeneca PLC earned $10.22B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.4%.How much cash and debt does AZN have?
AstraZeneca PLC reported $5.71B in cash and cash equivalents and $27.82B of debt on its most recent balance sheet in SEC filings.Is AstraZeneca PLC (AZN) hiring?
AstraZeneca PLC lists 859 open roles on its careers site as of Nov 22, 2026.Where does AZN stock trade?
AstraZeneca PLC (AZN) is listed on NYSE.What sector and industry is AZN in?
AstraZeneca PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AstraZeneca PLC go public?
AstraZeneca PLC (AZN) completed its IPO in 2026.Does AZN pay a dividend?
AZN's most recent ex-dividend date was 2026-08-07 with a cash dividend of $1.06 per share. No future ex-date is on file yet.What are analysts saying about AZN?
Across the last 8 analyst actions on AstraZeneca PLC, there were 2 upgrades and 2 downgrades. The most recent action was from Deutsche Bank: Hold on 2026-09-15. Recent price targets cluster around $75.00.What companies are similar to AZN?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), SNY (Sanofi), PFE (Pfizer Inc.), LLY (Eli Lilly and Company). Compare AZN side-by-side with any of them on Quantisnow.How can I track AZN on Quantisnow?
Quantisnow aggregates AstraZeneca PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZN to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change

